In a phase II study of patients with advanced cancer, elevated serum GDF15, and cachexia, the GDF15 inhibitor ponsegromab was associated with a median weight gain of approximately 2.81 kg compared with placebo at 12 weeks (24). This evidence concerns the gene GDF15 and cancer.